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Abstract
Background: People with severe mental illnesses (SMI) are at increased risk of cardiovascular disease (CVD). Clinical
guidelines recommend regular screening for CVD risk factors. We evaluated a nurse led intervention to improve
screening rates across the primary-secondary care interface.
Methods: Six community mental health teams (CMHTs) were randomised to receive either the nurse led
intervention plus education pack (n = 3) or education pack only (n = 3). Intervention (6 months): The nurse
promoted CVD screening in primary care and then in CMHTs. Patients who remained unscreened were offered
screening by the nurse. After the intervention participants with SMI were recruited from each CMHT to collect
outcome data. Main outcome: Numbers screened during the six months, confirmed in General Practice notes.
Results: All six CMHTs approached agreed to randomisation. 121 people with SMI participated in outcome
interviews during two waves of recruitment (intervention arm n = 59, control arm n = 62). Participants from both
arms of the trial had similar demographic profiles and rates of previous CVD screening in the previous year, with
less than 20% having been screened for each risk factor. After the trial, CVD screening had increased in both arms
but participants from the intervention arm were significantly more likely to have received screening for blood
pressure (96% vs 68%; adjusted Odds Ratio (OR) 13.6; 95% CI: 3.5-38.4), cholesterol (66.7% vs 26.9%, OR 6.1; 3.2-11.5),
glucose (66.7% vs 36.5% OR 4.4; 2.7-7.1), BMI (92.5% vs 65.2% OR 6.5; 2.1-19.6), and smoking status (88.2% vs 57.8%
OR 5.5; 3.2-9.5) and have a 10 year CVD risk score calculated (38.2% vs 10.9%) OR 5.2 1.8-15.3). Within the
intervention arm approximately half the screening was performed in general practice and half by the trial nurse.
Conclusions: The nurse-led intervention was superior, resulting in an absolute increase of approximately 30% more
people with SMI receiving screening for each CVD risk factor. The feasibility of the trial was confirmed in terms of
CMHT recruitment and the intervention, but the response rate for outcome collection was disappointing; possibly a
result of the cluster design. The trial was not large or long enough to detect changes in risk factors.
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Background
People with severe mental illnesses (SMI), such as schi-
zophrenia and bipolar disorder, have elevated rates of
cardiovascular disease (CVD) which is a greater cause of
premature death than suicide [1-3]. Younger people
with SMI are over three times more likely to die from a
heart attack, while those between 50 and 75 years of age
have a two-fold risk [3]. The reasons are manifold and
include traditional cardiovascular risk factors such as
smoking [4,5], diabetes [6] and dyslipidaemia [5,7,8].
Evidence regarding excess hypertension is more variable.
Antipsychotic medications may exacerbate cardiovascu-
lar risk through glucose dysregulation, weight gain or
dyslipidaemia [9,10]. People with SMI also eat less nutri-
tious diets and are less likely to undertake even moder-
ate levels of physical activity [4,11].
The physical health of people with SMI has become
an international priority and in the United Kingdom
(UK) both government and statutory organisations have
emphasised the provision of physical health care and
screening for people with SMI [12,13].
The UK National Institute for Health and Clinical
Excellence (NICE) recommends routine screening for
cardiovascular risk factors for people with SMI including
both schizophrenia and bipolar disorder [14,15]. This
risk assessment should be in line with recognised CVD
risk prediction models such as the 10 year Framingham
risk score [14]. Such models involve assessment of
smoking and diabetic status as well as lipids and blood
pressure. These individual risk factors are then com-
bined with a person’s age and sex in a CVD risk model
which determines the overall likelihood of incident CVD
in the next 10 years, as a percentage. The combined
algorithms are more powerful predictors of future CVD
than individual risk factors.
There is some debate regarding the best model of care
for this screening and whether generalist or specialist
models would be more effective. Generalist primary care
services are more familiar with CVD screening, but may
be less confident in working with SMI patients. Each
general practice is only responsible for a relatively small
number of SMI patients. Conversely, specialist Commu-
nity Mental Health Teams (CMHTs) have expertise in
SMI but are often unfamiliar with cardiovascular screen-
ing. The UK guidance recommends a model where this
CVD care should be provided within primary care set-
tings (general practice) but there is an expectation that
specialist CMHTs and other secondary care psychiatric
services will have a role in ensuring this screening has
taken place.
There is a further expectation that people receiving
antipsychotic medication should receive monitoring of
their BMI and cardiovascular risk at start of treatment
and periodically thereafter [9]. This might suggest a spe-
cialist secondary care model for screening. Conversely,
in the UK general practices are given incentives to keep
an SMI register and to provide patients with an annual
review and health check [16,17]. However the contract
does not specifically include screening for cardiovascular
risk factors.
In England, secondary psychiatric care is organised
according to the National Service Framework for Mental
Health [18] and each geographical area is covered by
one Community Mental Health Team, funded publically
by the National Health Service. These CMHTs are mul-
tidisciplinary and each key worker has a caseload of
people with SMI, whose care they coordinate according
to the care programme approach (CPA). Regular review
meetings are held under the CPA to review unmet
needs and arrange appropriate biological, psychological
and social management, including physical health. How-
ever since people with SMI receive both specialist and
general practice services, there may be confusion about
the provision of cardiovascular screening and other phy-
sical health initiatives unless communication is clear.
Evidence from clinical settings suggests that rates of
CVD screening do not meet national SMI guidelines,
either in primary or secondary care. A study of 1966
patients in UK assertive outreach teams revealed that
only 26% had received screening for blood pressure, 17%
for BMI, 28% for glucose and 22% for lipids [19]. In a dif-
ferent study in a primary care setting, people with schizo-
phrenia were significantly less likely to receive screening
for blood pressure or cholesterol as matched practice
controls [20]. In the SMI group, 55.9% received a blood
pressure reading in the preceding three years, 39.5% a
weight and 12.3% a lipid measurement [20].
We developed a nurse-led intervention to improve
rates of cardiovascular screening for people with SMI.
Nurse-led interventions have proved successful in other
areas of cardiovascular care, in both specialist and gener-
alist settings. In the UK, a specialist nurse-led clinic for
patients with diabetes demonstrated significant reduc-
tions in cholesterol and blood pressure in a randomised
trial [21]. The intervention included regular 4-6 weekly
reviews, including titration of drug therapies and lifestyle
advice. An international literature review of nurse-led
interventions concluded that general practice nurses have
a potentially potent role in chronic disease management,
including heart failure. However the authors stated that
higher level evidence is required to determine and impact
of such interventions and the most important roles and
elements of such interventions [22].
We conducted a phase-two randomised feasibility trial
to evaluate the short term impact of our nurse-led inter-
vention. The nurse worked across the primary-
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secondary care interface to improve screening rates for
people with SMI. In the UK, this collaboration between
specialist CMHT services and general practice services
is facilitated because each CMHT is aligned to a handful
of defined general practices within the same geographi-
cal area. Primary and secondary care services share the
care of people with SMI.
Objectives and hypothesis
(a) To determine the short term impact of a nurse-led
intervention to increase rates of cardiovascular screening
for people with SMI in CMHTs, compared to ‘treatment
as usual’ plus a CMHT staff education pack.
(b) To determine the feasibility of a full-scale rando-
mised controlled trial of the nurse led CVD screening
intervention in SMI.
We hypothesised that, compared to usual care, a
CMHT-based nurse led intervention would increase the
rate of screening for cardiovascular risk factors in people
with SMI
Methods
Development of the Intervention
We undertook trial development work in line with the
existing UK Medical Research Council framework for
developing a complex intervention such as this [23].
Complex interventions are defined as those that include
several components [23]. Our intervention included a
number of elements including liaison with general and
specialist clinicians, prompting them provide CVD
screening (including smoking, blood pressure, random
blood glucose and lipids), obtaining the CVD screening
results and then providing screening where gaps or
omissions were identified.
The development work for this intervention included
interviews with service users, doctors, nurses and social
workers from both primary and secondary care, all with
the aim of designing an intervention to improve cardio-
vascular screening rates for people with SMI [24]. There
was considerable variance in the preferences of profes-
sionals and services users regarding the best setting for
the intervention and whether a primary care (generalist)
model or specialist model should be provided. In quali-
tative interviews, most professionals believed primary
care should take the lead, while service users were more
divided, with a significant number preferring their men-
tal health team to provide screening. No single model of
care seemed to meet all professional and service user
requirements, and a minority of mental health profes-
sionals were opposed to providing this form of care.
The optimal model, addressing different these different
preferences, was one which initially concentrated on pri-
mary care screening, with the back up of screening in
secondary care when primary care screening failed to
occur. Respondents in the development work stated that
this “best model” would require dedicated coordination
and extra capacity when CVD screening had not
occurred in either primary or secondary care. When the
option of an additional nurse to coordinate this work
was discussed in the development work [24] most parti-
cipants preferred this model.
On the basis of these findings we designed a nurse-led
intervention based in secondary care but working across
the interface between primary and secondary care. The
intervention included three phases of screening. First,
the nurse would promote screening in primary care by
liaising with the general practice. Second the nurse
would encourage CMHT workers to screen patients
who had not received Primary Care screening after
three months. Finally, if screening had still not occurred
after a month, the nurse would offer screening to the
patient herself.
Study Design
This was a cluster randomised feasibility trial, with com-
munity mental health teams (CMHTs) as the unit of
randomisation. We chose the cluster design for both
clinical and methodological reasons. Clinically, the clus-
ter design more closely mirrors real clinical practice.
The methodological benefit of the cluster design is that
it minimises the risk of “contamination” likely to occur
in an individually randomised trial. This contamination
would involve leakage of the intervention into the
“Treatment as Usual” arm which might artificially ele-
vate the rates of cardiovascular screening by General
Practitioners (GPs) or CMHTs in the treatment as usual
arm.
We compared two interventions to improve screening
rates for CVD risk factors and the management of these
risk factors among patients on CMHT caseloads. Teams
in the intervention arm received the nurse-led screening
programme as well as an education pack regarding
appropriate screening for CVD related risk factors.
Teams in the treatment as usual arm only received the
education pack. We included the education pack to
ensure that we were comparing the intervention with
the best possible routine care.
Setting and eligibility
We invited sequential CMHTs in Camden and Islington
Mental Health and Social Care Trust in North London,
to participate in the trial. Potential participating teams
were selected at random from the existing 13 CMHTs
in three geographical areas of the Trust, namely Isling-
ton, North and South Camden. We aimed to recruit two
CMHTs from each area (total six CMHTs) which would
agree to randomisation. The intervention was aimed at
all patients whose care was coordinated by a key worker
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at an enhanced level on the general adult CMHT case-
load. This includes those with a recorded diagnosis of
schizophrenia, schizoaffective disorder, bipolar disorder,
persistent delusional disorder, non-organic chronic psy-
chosis or other severe mental illness in the clinical
notes.
Randomisation and allocation concealment
Participating CMHTs were randomly allocated to each
arm of the trial using a sealed envelope method. A sta-
tistician uninvolved in the trial randomly generated
treatment allocation numbers to which both the
researcher and nurse were blind. The randomisation
was stratified by the three geographical areas in the
Trust, namely North Camden, South Camden and
Islington. Once two CMHTs in each geographical area
had agreed to participate, the envelopes were opened to
determine the allocation for each CMHT. After rando-
misation it was not possible for the researcher, the
CMHT workers or the patients to remain blind to allo-
cation. The researcher could not remain blind to which
arm the CMHTs had been allocated to when she
assessed satisfaction with the intervention and who had
performed screening (GP, CMHT worker or nurse).
Therefore, during the evaluation phase, the possibility of
observer bias was decreased by obtaining information
on the main outcome directly from primary care clinical
notes.
Nurse-led intervention arm
The nurse was employed to work at the three CMHTs
in the intervention arm. The nurse was a registered gen-
eral nurse with previous experience of previous experi-
ence of providing cardiovascular screening. She did not
have specific mental health qualifications.
The intervention lasted six months and targeted
improving the levels of recording of the CVD risk fac-
tors required to estimate 10 year cardiovascular risk,
namely smoking status, blood pressure and a non-fast-
ing blood test for serum lipids and glucose. The main
concepts of the intervention included establishing a sys-
tem to monitor whether cardiovascular screening had
occurred and sending prompts to primary and second-
ary care staff if screening had not occurred. Finally the
nurse offered screening herself to cover patients who
still had not received the complete battery of CVD
screening. The elements of the intervention are con-
tained in table 1. When the measurements were per-
formed by the nurse herself they included laboratory
tests for non-fasting serum levels of cholesterol, high
density lipoprotein (HDL) cholesterol and random glu-
cose. Current smoking status was recorded as well as
resting blood pressure, measured by an automatic, cali-
brated sphygmomanometer. Body Mass Index is not
part of the ten year cardiovascular risk scores, but it was
calculated using calibrated scales for weight and stan-
dardised height measurement.
The nurse-led intervention did not include a theoreti-
cal behavioural change approach.
The teams also received an education pack which is
described below.
Comparison arm
CMHTs in the comparison arm did not receive any
input by the nurse. However, they were informed of the
nature of her work, the national recommendations for
screening and which risk factors were required. They
also received the education pack.
Education pack
CMHTs in both arms of the trial were given an educa-
tion pack including the following written information.
1) A summary of the evidence that CVD and CVD
risk factors are more prevalent in SMI than in the
general population.
2) Copies of guidelines and consensus papers which
recommend the monitoring of physical health for
clients with SMI
3) Information about CVD, appropriate screening for
CVD risk factors and their abnormal thresholds and
risk reduction interventions
4) A supply of patient booklets on CVD and risk
reduction interventions
Evaluation phase and Outcomes
Our primary outcome was the proportion of patients
who had received screening for each risk factor by the
end of the six month trial. The denominator was the
number of people who had not been screened for each
risk factor during the previous year. We also recorded
who provided this screening and whether any interven-
tions were received for identified risk factors. To
decrease response bias in either trial arm, the main out-
come data was defined as a record of screening in the
primary care notes, rather than self-report. Trial process
outcomes included the feasibility of i) recruiting and ii)
randomising CMHTs to the trial and iii) obtaining out-
come data regarding screening directly from patients
and from their GP notes. The Secondary outcome was
satisfaction with CVD screening, using the Client Satis-
faction Questionnaire (CSQ-8) [25].
Outcome data collection and sample size
The intervention lasted for six months and was offered
to all patients on the CMHT caseload. Potential partici-
pants were contacted to obtain outcome data at the end
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of the trial. For the three months after its completion
we collected outcome data on rates of screening from a
sub-sample of patients in each of the 6 participating
CMHTs. Potential participants with SMI were randomly
selected from each CMHT caseload in batches of 20.
The care-coordinator then confirmed whether the
patient was eligible, according to the inclusion criteria
below. Those eligible were sent a signed letter from the
care-coordinator inviting them to attend a pre-arranged
research interview. We aimed to recruit 75 participants
in each arm of the trial within three months of the end
of the nurse-led intervention. This number was chosen
for exploration of trial feasibility rather than by a formal
sample size calculation.
Eligibility criteria for outcome interview
The inclusion criteria for the research interview were all
patients with a diagnosis of SMI, aged between 18 and
75, on the CMHT caseload. We excluded those who
were currently “too unwell” or unwilling to participate,
which was defined i) by their care-coordinator or ii) by
current inpatient admission or iii) receipt of home treat-
ment from the crisis resolution team.
The majority of research interviews were conducted at
the CMHT base and participants were reimbursed £10
for their time. Participants gave written informed con-
sent to participate and permission was sought to access
their GP notes and clinical record, to confirm whether
screening had been performed and if any relevant inter-
ventions provided. An interpreter was offered if the
patient did not understand English sufficiently.
Measurements in evaluation interview
The structured research interview for consenting partici-
pants ascertained the following: 1) Demographic details,
clinical diagnosis and current psychotropic medication,
2) Whether screening for each risk factor had occurred
in the year before the trial and during the trial period 3)
The date, content and provider of this screening by self
report 4) Any CVD risk factors detected 5) Relevant
interventions for each risk factor were recorded in parti-
cipants whose BP, BMI, glucose or cholesterol were
above normal ranges, or who were smokers. 6) The
CSQ-8 [22]; which produces a score between 8 and 32;
higher scores indicating greater satisfaction, and 7) Con-
sent to check GP notes to confirm CVD risk factor
screening, dates and any relevant interventions provided.
After the interview, information about CVD screening
and interventions was obtained from the participant’s
computerised GP notes, using a standardised form
which was completed by the researcher (who visited the
practice) or by the practice staff.
Data collection in the feasibility trial was time limited
to three months after the intervention, due to funding
Table 1 Description of Nurse led intervention to promote screening for cardiovascular risk factors in people with SMI
on the CMHT caseload
Phase of screening Components of intervention
Orientation Write to all General Practitioner (GP) and community mental health teams (CMHTs) in the
intervention arm to inform them of the nurse’s work and the trial
Phase one: Liaison with primary care to
prompt CVD screening
Months 1-3
-Create secure lists and database of all patients under the care of CMHT, including address of GP.
-Nurse writes to the GP of every patient explaining the rationale and evidence base for annual
screening of cardiovascular risk in people with SMI
i) Request that results of relevant CVD screening in the past year are sent to the nurse (including
smoking and diabetic status, glucose, lipids, blood pressure and 10 year cardiovascular risk score).
A proforma was provided.
ii) Request that screening is arranged to assess any missing cardiovascular risk factors
-When no response was received, up to two reminders were sent to the GP at 2 weekly intervals.
Phase two: Liaison with secondary care to
prompt CVD screening
Month 4
-Determine which patients have missing CVD risk factors on the nurse database.
-Contact CMHT key worker for each of these patients.
-Provide them with evidence and rationale for CVD screening in SMI
-Request that they organise screening for missing CVD risk factors (including the same risk factors as
phase one)
-CMHT workers were provided with pathology request forms.
-Request that they communicate the results back to nurse
Phase three: Invitation to cardiovascular
screening with nurse
Months 4-6
-Determine which patients have still not been screened by GP or CMHT key worker
-Write to patient explaining importance of annual CVD screening
-Invite patient to attend a scheduled CVD screening appointment with nurse at CMHT base.
(including the same risk factors as phase one)
-All results were sent to the patient and their GP
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of the feasibility work. This allowed two waves of
recruitment of participants. The first recruitment wave
occurred in all six participating CMHTs. However there
was only sufficient time for the second recruitment
wave to occur in four CMHTs (two in the intervention
arm, two in the comparison arm).
Ethical Approval
The trial was approved by the Camden and Islington
Local Research Ethics Committee.
Statistical methods
First, we compared demographic and clinical variables
for participants from each trial arm and established how
many had not been screened for each risk factor during
the preceding year. For those who had not been
screened, we compared the proportions with a GP
record of each test by the end of the trial in each arm
using logistic regression to generate odd ratios with
robust standard errors to adjust for the cluster nature of
the trial, age and gender. The unit of cluster was the
CMHT. We also used Chi squared tests to compare the
proportions with each risk factor who had received an
appropriate intervention for it. Differences in satisfaction
in the two trial arms were analysed by comparing mean
CSQ scores using a t test.
Results
Each of the first six CMHTs approached agreed to parti-
cipate in this feasibility trial. Figure 1 is an adapted
CONSORT diagram for a cluster trial, showing the flow
of CMHTs through the trial. The nurse attempted to
organise cardiovascular screening for all of the 436 peo-
ple in the three CMHTs which were randomised to the
intervention arm.
Response rates for research interviews
A total of 121 research participants were recruited, 59
from CMHTs in the intervention arm and 62 from
CMHTs in the comparison arm. The participation rates
in the two sequential recruitment waves can be viewed
in figures 2 and 3. 105/428 (24.5%) eligible participants
attended interview in recruitment wave one (figure 2),
and 258/428 participants were identified by care coordi-
nators as eligible for re-invitation in wave two. In wave
two, 73 of these eligible potential participants were
invited in four CMHTs and 16 (21.9%) attended (figure
3).
Comparison of trial arms
The demographic and clinical profiles of the 121
research participants from the two arms of the trial are
compared in table 2. There were no statistically signifi-
cant differences in the age, gender or ethnicity of
participants in each trial arm. They had similar psychia-
tric diagnoses in their notes and reported no differences
in current CVD risk factors. The proportions that had
been screened for CVD risk factors in the year prior to
the trial were also similar but low (results confirmed in
GP notes). Less than a fifth of all participants had a
record of BMI, blood pressure or smoking status in the
previous year and about one in ten had received a blood
test for glucose or lipids (table 2).
The rates of screening for each CVD risk factor during
the trial are compared in table 3. Within the three
months of the trial there were 6 patients (one in the
intervention arm and 5 in the control arm) for whom it
was not possible to arrange to review GP notes for prac-
tical reasons (n = 2) or lack of consent (n = 4). They
were excluded from further analysis leaving 58 partici-
pants with confirmed outcome data in the intervention
arm and 57 in the control arm (table 3).
By the end of the six month trial, the numbers who
had received screening increased in both arms. In the
control arm, around two thirds now had a record of
BMI, smoking or blood pressure and approximately one
in three had received a blood test for glucose and/or
cholesterol (table 3). Participants in the intervention
arm were significantly more likely to have received
screening for all CVD risk factors during the trial, with
an absolute increase of about 30% for each risk factor.
Within the intervention arm, approximately half the
screening had been provided by general practice and
half by the nurse (table 4). No CVD screening was pro-
vided by CMHT workers during the month that they
were asked to organise this. In the control arm, screen-
ing was nearly always provided by general practice (or
infrequently by other medical services) with the excep-
tion of two patients for whom smoking status was
recorded by the CMHT. There was no significant differ-
ence in satisfaction with CVD screening provision
between the two arms (intervention arm mean (sd)
CSQ-8 score: 24.7 (4.6), control arm: 23.4 (5.2); mean
difference 1.5 (95% CI: -0.4-3.3) t test p = 0.12).
The study was designed to evaluate outcomes by
recruiting participants at the end of the trial, rather than
collecting data from CMHTs throughout the trial. How-
ever the cardiovascular nurse did report the proportion
of the 436 CMHT patients in the intervention arm who
required screening for each risk factor because they had
not been screened in the previous year. She also
recorded how many of these had been screened by the
end of the six month intervention. These were as fol-
lows; 342 people had not received a blood pressure
reading in the previous year and 259 (75.7%) of these
were screened by the end of the trial. An annual choles-
terol measurement was needed for 371 patients and 158
(42.5%) were finally screened. Random glucose was
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required for 342 and 189 (55.2%) were screened. Finally
350 people needed a BMI and 227 (64.8%) had been
measured by the end of the trial.
Table 5 outlines interventions received by participants
whose screening had identified CVD risk factors such as
diabetes, smoking or dyslipidaemia. The majority had
received lifestyle advice in both arms, and similar num-
bers were prescribed relevant pharmacological interven-
tions and/or received further screening for the risk
factor.
Discussion and Conclusion
Main findings
The nurse-led intervention, working to improve CVD
risk factor screening in SMI across the primary-second-
ary care interface, significantly increased the proportion
of CMHT patients who received such screening over six
months. These results apply to the people who partici-
pated in the research interviews at the end of the trial.
Rates of screening for all CVD risk factors increased for
participants from both arms of the trial, but to a
Figure 1 Flow of CMHTs through feasibility trial.
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significantly greater degree in the nurse-led intervention
arm. This resulted in approximately 30% more eligible
patients being screened for each risk factor, including
BMI, blood pressure and smoking status, as well as
lipids, glucose and “Framingham” 10 year CVD risk
score. However, even in the nurse-led intervention arm,
a third of participants with SMI had not taken up a
blood test by the end of the six month intervention and
only a third had been apportioned a 10 year Framing-
ham risk score. In the treatment as usual arm, two
thirds had still not taken up a blood test and only one
in ten had a ten year risk score. For those with identi-
fied risk factors, there was no difference in provision of
relevant behavioural or pharmacological interventions
between the two arms.
The baseline screening results highlight how few peo-
ple with SMI currently receive CVD screening each year
in general practice. Our findings were in line with pre-
vious research showing around one in ten people with
SMI have been screened for cholesterol in primary care,
in the last three years [20].
Strengths
We chose a cluster design, whereby the unit of rando-
misation was the CMHT rather than the individual,
because this design prevents contamination in the
treatment as usual arm. If patients had been individually
randomised to the nurse, those who were randomised
“out” might access better treatment than usual because
CMHT workers would be aware that their patients were
not receiving the care of the screening nurse.
The magnitudes of both the absolute and relative
increases in screening rates were fairly consistent across
all risk factors and all increases were of clinical
significance.
Limitations
The response rate in the recruitment for outcome data
was a major limitation of the study and this would need
addressing in future trials. We aimed to recruit up to 75
people from each arm of the trial to assess the feasibility
of outcome data collection, and fell slightly short of this
target. The recruitment was time limited because of
funding, but all SMI patients who were well enough
received at least one invitation to a fixed research inter-
view appointment in wave one. Recruitment of patients
in CMHTs to research often requires intense effort and
we did not have sufficient time for this. Consequently
the participants who provided outcome data may have
been a biased sample of CMHT patients and the gener-
alisability of our results cannot be guaranteed. However
Figure 2 First wave of recruitment to research interviews (Six
teams involved). Figure 3 Second Wave of recruitment to research interviews
(Four teams involved).
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Table 2 Comparison of demographic characteristics of participants in each arm of the cluster trial
Intervention Arm Control
Arm
Significance level (chi square except age = t test)
(n = 59) (n = 62)
Mean age (SD) 42.0 (sd 10.52) 43.1 (sd 12.91) 0.600
Age range 21-65 20-67
Gender
Male 39 66% 34 55% 0.206
Female 20 34% 28 45%
Ethnic Origin
Asian 5 8.5% 2 3%
Black 13 22% 9 15%
White 37 63% 42 68% 0.243
Other 4 7% 9 15%
Employment Status
Employed 4 7% 3 5%
Unemployed/looking for work 0 0% 1 2%
Long-term sickness or disability allowance 43 73% 36 58%
Retired 1 2% 1 2% 0.397
Looking after family or home 2 3% 1 2%
Education 4 7% 8 13%
Voluntary work 5 8% 12 20%
Diagnosis in clinical notes
Schizophrenia 29 50% 27 44%
Bipolar Affective Disorder 13 22% 14 23% 0.291
Schizoaffective Disorder 4 7% 0 0%
Other Psychotic Disorder 2 3% 4 7%
Other diagnosis* (on enhanced level CPA) 10 17% 17 28%
Antipsychotics
First generation 11 19% 7 11% 0.323
Second generation 40 68% 38 61% 0.785
Self-reported CVD risk factors
Current smoker 40 68% 39 63% 0.572
Overweight or obese 32 54% 37 60% 0.546
Raised cholesterol 18 31% 15 24% 0.436
Hypertension 10 17% 10 16% 0.903
Diabetes or raised glucose 8 14% 6 10% 0.505
Screening received in year prior to trial
BP 6 10% 13 21% 0.103
BMI 5 9% 12 20% 0.850
Glucose 7 12% 5 8% 0.485
Cholesterol 7 12% 5 8% 0.503
Smoking status 6 10% 12 19% 0.167
10 year cardiovascular risk score 1 2% 2 3% 0.609
*includes depressive disorder, personality disorder or anxiety disorder.
SD standard deviation. BP. Blood pressure. BMI. Body Mass Index. CPA Care Plan Approach.
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the main findings rely on comparison of screening rates
between participants from the two arms and there was
no evidence of differential selection bias between partici-
pants from the two arms. They were similar in terms of
demographics, diagnoses and antipsychotic medication.
Most importantly there was no evidence that they dif-
fered in terms of their cardiovascular risk factors or
their previous access to health care. Similar numbers of
participants had received previous screening for CVD
risk factors in both arms of the trial. Therefore there is
little evidence of bias in the main risk factors for partici-
pants in each arm of the trial.
The intervention was designed to complement the
configuration of United Kingdom primary and second-
ary care services and its international generalisability
will therefore depend on local arrangements for service
provision.
Feasibility findings
Although delivering the intervention proved feasible, a
major burden in the trial was organisation and adminis-
tration across the primary-secondary care interface.
Although GPs often write to CMHTs, they do not regu-
larly convey the results of physical health tests to
CMHTs. The cardiovascular nurse spent many hours
writing and requesting screening results from practices
and whilst many were forthcoming, this was extremely
time consuming. Some GPs also questioned the ratio-
nale for requesting this information and others felt
uncomfortable being asked to perform physical health
tests by a nurse from mental health services. This issue
has partly been resolved by the latest UK NICE guide-
lines on schizophrenia [14] which state that CVD
screening results should be passed between primary and
secondary care in both directions. If the current inter-
vention were implemented in CMHTs, administrative
support would free up more time for the nurse to focus
on clinical activity.
Six months was also too short a period for the nurse
to be able to deliver interventions for people with ele-
vated risk factors, since many of the screening results
only became available towards the end of the period.
Unless screening results can be obtained far more
rapidly from primary care, future trials of this type of
intervention would need at least a further six months to
be able to demonstrate an impact on cardiovascular risk
in people with SMI.
Clinical implications
This trial provides evidence that a nurse working in
CMHTs has far more impact on rates of CVD screening
than an education pack alone. Our findings also demon-
strate the clinical need for such interventions; few partici-
pants with SMI had received annual screening for CVD
risk factors prior to the trial. By the end of the trial, few
patients in the control arm had received screening for all
cardiovascular risk factors, despite the teams showing
interest in the subject by participating in the trial and
Table 3 Proportions screened for each cardiovascular risk factor at six months
CVD risk factor Nurse arm
(n = 58)
Control arm
(n = 57)
OR 95% CI Adj OR1 95% CI Adjusted z test p value1
Blood pressure N needing screen2 52 44
N screened % 50 96.2 20 68.2 11.7 3.5 - 38.4 13.6 3.9 - 47.3 0.001
Cholesterol N needing screen 51 52
N screened % 34 66.7 14 26.9 5.4 3.2 - 9.1 6.1 3.2 -11.5 0.001
Glucose N needing screen 51 52
N screened % 34 66.7 19 36.5 3.5 2.4 - 5.1 4.4 2.7 - 7.1 0.001
BMI N needing screen 53 46
N screened % 49 92.5 30 65.2 6.5 2.0 - 21.6 6.5 2.1 - 19.6 0.001
Smoking status N needing screen 51 45
N screened % 45 88.2 26 57.8 5.5 3.0 - 9.9 5.5 3.2 - 9.5 0.001
Framingham score N needing screen 55 55
N screened % 21 38.2 6 10.9 5.0 1.5 - 16.5 5.2 1.8 - 15.3 0.003
Table 3 only includes participants whose GP notes could be examined to confirm screening.
1. Adjusted for age and gender.
2. Needing screening was defined as not having received screening for that risk factor within the previous year
CVD. Cardiovascular Disease. BMI Body Mass Index. CMHT Community Mental Health Team. OR Odds Ratio.
Table 4 Provider of screening in intervention arm
CVD risk factor General practice CMHT Trial Nurse
Blood pressure 24 48.0% 2 4.0% 24 48.0%
Cholesterol 17 50.0% 0 17 50.0%
Glucose 17 50.0% 0 17 50.0%
BMI 25 51.0% 1 2.0% 23 46.9%
Smoking status 21 47.7% 0 24 53.3%
Framingham score 5 23.8% 0 16 76.2%
Osborn et al. BMC Health Services Research 2010, 10:61
http://www.biomedcentral.com/1472-6963/10/61
Page 10 of 13
receiving the education pack regarding CVD screening.
There was no evidence that CMHT workers provided
CVD screening themselves in either arm of the trial. In
the nurse-led intervention arm it is possible that staff
were aware that screening would subsequently be pro-
vided by the nurse, so felt less compelled to organise
screening themselves. However the lack of CMHT
screening in the treatment as usual arm suggests that it
may be difficult to achieve compliance with recent NICE
guidelines which recommend that secondary care pro-
vides screening for any patients who have not received
such care within general practice. Our findings suggest
that this would require resource across the primary-sec-
ondary care interface and that basic training or education
for teams would be minimally effective.
Improving CVD screening is only the first step in pre-
venting cardiovascular disease and we need different
trials to determine whether identified risk factors can be
reduced by specialist or general interventions for people
with SMI. Our trial was based in a specialist setting and
it maybe that interventions set in generalist, primary
care settings and run by practice nurses would be more
successful in the future. This trial was not long enough
for the nurse to provide interventions to effect beha-
viour change.
The satisfaction survey revealed high levels of satisfac-
tion with physical health care services in both arms of
the trial. This reinforces previous evidence that service
aimed at improving the physical health of people with
SMI are acceptable [26].
Research implications
The poor response rate for outcome data collection in
our trial would need addressing in future studies and
our study design would need major modifications. One
option would be to return to an individually randomised
design despite the potential for contamination of the
intervention between the arms of the trial. If a cluster
design were adopted, greater effort would be needed to
permit outcome data collection in most SMI patients.
This might require special ethical consideration. One
possibility is that all SMI patients in a CMHT be asked
for permission to record screening rates from their GP
notes, perhaps with an opt out clause. However, any
research requiring more complex outcome data collec-
tion, and interviews with patients, would encounter
similar difficulties to the current study.
Future cardiovascular studies in SMI need to build on
the brief intervention we tested. While the nurse-led
intervention appears simple, it was organisationally
complex. Challenges included working across the
Table 5 Interventions provided during trial following detection of cardiovascular risk factors
Intervention arm
(n = 59)
Control arm
(n = 57)
Chi square p value
High blood pressure1 (n = 10) (n = 9)
Re-measured 7 70% 7 78% 0.701
Diet advice 9 90% 9 100% 0.330
Exercise advice 8 80% 6 67% 0.510
Anti-hypertensive 7 70% 8 89% 0.313
Obesity1 (n = 32) (n = 34)
Re-measured 14 44% 19 44% 0.976
Diet advice 21 66% 23 68% 0.608
Exercise advice 21 66% 20 59% 0.569
Anti-hypertensive 6 19% 7 21% 0.851
Smoker1 (n = 39) (n = 37)
Advice 35 90% 32 87% 0.660
Referral to services 19 49% 18 49% 0.995
Nicotine replacement therapy 16 41% 19 51% 0.367
Dyslipidaemia1 (n = 18) (n = 15)
Re-measured 7 39% 5 33% 0.741
Diet advice 15 83% 12 80% 0.805
Exercise advice 10 56% 10 67% 0.515
Statin prescribed 7 39% 8 53% 0.670
Diabetes/raised glucose1 (n = 8) (n = 6)
Diet advice 7 88% 4 67% 0.347
Exercise advice 7 88% 2 33% 0.036
Oral Hypoglycaemic
prescribed
5 63% 4 67% 0.872
1. Clinical diagnosis/status confirmed in General Practice clinical notes.
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primary-secondary care interface and recruiting enough
patients from CMHTs. Future trials need to be long
enough for risk factors to be identified, addressed and
then re-measured. The medium term end-point or out-
come of such trials should be overall ten year cardiovas-
cular risk scores. These trials need to be large enough
for the proportions of people with identified CVD risk
factors to generate statistical power to show differences
in the reduction of ten year cardiovascular risk scores.
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